Emergent BioSolutions reported Q3 2026 total revenues of $110.0 million but swung to a net loss of $32.7 million. The company also announced a $75 million repurchase of Senior Unsecured Notes and updated its leadership structure.
Emergent BioSolutions reported Q3 2026 total revenues of $110.0 million but swung to a net loss of $32.7 million. The company also announced a $75 million repurchase of Senior Unsecured Notes and updated its leadership structure.